Pharmafile Logo

Peter Impey

- PMLiVE

EMA cuts back as Brexit staff losses top expectations

Regulator says it faces loss of 30% of staff

- PMLiVE

Immunology keeps Shire figures solid as Takeda takeover nears

Shire’s sales increased by 6% to $3.81bn

- PMLiVE

Pfizer CEO reckons rebates will disappear, and that’s a positive

The move also has the support of FDA Commissioner Scott Gottlieb

- PMLiVE

Sanofi latest to reveal Brexit stockpiling of drugs

Company says UK job losses inevitable in event of hard or no deal Brexit

- PMLiVE

Ipsos to buy GfK Research divisions

Customer experience, experience innovation, health and public affairs all acquired

How behavioural design is transforming the role and impact of life sciences in healthcare

Behavioural economics will become essential to the future success of life sciences companies

- PMLiVE

Bringing the NHS into the 21st century

As the NHS celebrates its 70th birthday and a £20bn “birthday gift” from the UK government, we find out how one company is delivering what the National Health Service really...

Blue Latitude Health

- PMLiVE

First migraine prevention drug to hit European market

European Commission green lights Novartis’ Aimovig

- PMLiVE

Bluebird Bio: on the cusp of a gene therapy revolution

Nick Leschly talks to PME about Bluebird's remarkable gene therapy pipeline and why it’s filing first in Europe.

- PMLiVE

Indivior push to diversify boosted by schizophrenia drug approval

Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna

- PMLiVE

Dupixent bounce-back helps stem diabetes declines at Sanofi

CEO Brandicourt says Sanofi will “enter a new growth phase”

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links